MindWalk Holdings Corp.™, a Bio-Native AI company transforming life sciences data intelligence, today announced the appointment of industry veteran Thomas W. Lynch, Ph.D., as Chief Business Officer (CBO), effective October 20, 2025. This strategic hire is aimed at accelerating the commercial expansion of MindWalk’s HYFT-powered Deep Data platform across global pharmaceutical and biotechnology markets.
“Tom’s combination of biotech depth and software commercialization expertise directly supports MindWalk’s next path of growth,” said Dr. Jennifer Bath, CEO of MindWalk. “As we expand the reach of our Bio-Native AI platform worldwide, Tom’s leadership in scaling global teams and forging strategic partnerships will be instrumental in creating long-term shareholder value.”
Dr. Lynch brings over 20 years of experience at the intersection of biotechnology and software innovation. He is widely recognized for scaling global commercial organizations, launching high-impact scientific software and data platforms, and driving market adoption in highly complex technical environments. His career spans technical sales, client services, business development, and global commercial operations, consistently demonstrating the ability to translate scientific innovation into commercial success.
Most recently, Dr. Lynch served as Director of Technical Sales & Scientific Support at Aldevron, a global leader in plasmid, mRNA, and protein production services. There, he built and led a global commercial team, aligning strategies with scientific innovation and client needs. During his tenure, he drove initiatives that accelerated market adoption of advanced biologics services, helping position Aldevron as a leading provider in the life sciences industry. His efforts contributed to the company’s growth trajectory and were integral to Aldevron’s $9.6 billion acquisition by Danaher Life Sciences in 2021.
Prior to Aldevron, Dr. Lynch served as Vice President of Global Sales and Client Services, where he spearheaded initiatives including the launch of clinical mRNA manufacturing services and strategic account expansion. These programs materially advanced Aldevron’s market presence and demonstrated his ability to manage high-impact projects that bridge scientific innovation and commercial strategy.
Earlier in his career, Dr. Lynch led global commercial operations at DNASTAR, overseeing sales, distribution, and technical support while launching innovative software products designed for protein structure prediction and analysis. Among these, NovaFold powered by I-TASSER became a widely adopted platform for structural bioinformatics, exemplifying Dr. Lynch’s proven ability to bring complex scientific software to market effectively.
Dr. Lynch’s career reflects a consistent record of success in commercializing scientific technology, building high-performing global teams, and creating sustainable market adoption strategies for data-driven solutions in life sciences. His expertise uniquely positions him to support MindWalk as it scales its Bio-Native AI platform and captures a larger share of the multibillion-dollar life sciences data analytics market.
In addition to his corporate leadership experience, Dr. Lynch serves on the Board of BioForward, Wisconsin’s leading biohealth association. In this role, he has helped drive industry collaboration, education, and legislative initiatives, contributing to the growth and competitiveness of Wisconsin’s biohealth sector. His broad network and thought leadership further enhance his ability to forge partnerships that advance both commercial and scientific objectives.
“I am thrilled to join MindWalk at such an exciting stage in its growth journey,” said Dr. Lynch. “MindWalk sits at the frontier of AI-native data intelligence in life sciences. I look forward to helping translate its powerful technology into solutions that deliver measurable value for customers, partners, and investors alike.”
MindWalk’s Bio-Native AI platform, HYFT, is designed to transform the way life sciences organizations analyze and leverage complex datasets. By integrating artificial intelligence directly into the data architecture, HYFT enables rapid, actionable insights across research, clinical development, and operational workflows. This approach allows organizations to streamline decision-making, improve scientific outcomes, and accelerate the path from discovery to market.
The appointment of Dr. Lynch aligns with MindWalk’s strategic priorities to broaden adoption of its HYFT-powered platform and to expand its global footprint. With Dr. Lynch at the helm of business development, MindWalk aims to deepen relationships with pharmaceutical, biotechnology, and research organizations, while scaling partnerships and commercial initiatives that maximize platform impact and shareholder value.
“Commercial expansion is a key driver of our long-term strategy,” added Dr. Bath. “Dr. Lynch’s expertise in global market adoption and strategic growth initiatives positions MindWalk to capitalize on the rapidly evolving life sciences data landscape. His appointment strengthens our ability to scale operations and deliver value to a growing global customer base.”
Looking ahead, MindWalk plans to leverage Dr. Lynch’s experience to accelerate platform adoption in strategic markets worldwide, enhancing the company’s presence across North America, Europe, and Asia. By combining cutting-edge Bio-Native AI technology with deep commercial expertise, MindWalk is poised to redefine data intelligence in life sciences and empower organizations with insights that drive innovation, efficiency, and better outcomes for patients globally.
In summary, the addition of Dr. Thomas W. Lynch as Chief Business Officer represents a pivotal step in MindWalk’s growth trajectory. His proven record in biotechnology commercialization, software adoption, and global team leadership is expected to accelerate the company’s commercial expansion, strengthen strategic partnerships, and position MindWalk to capture a growing share of the life sciences data analytics market.
